$ASMB SEC Filings

Filed On	Filing
20 Aug 2026	S-8
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	8-K/A: Results of Operations and Financial Condition – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –
13 Aug 2026	SCHEDULE 13G/A
13 Aug 2026	10-Q
13 Aug 2026	8-K: Completion of Acquisition or Disposition of Assets
04 Aug 2026	SCHEDULE 13G/A
18 Jun 2026	Form 4: Bjorkquist Jeanette M, PFO and PAO Sold 29 shares ($674)
05 Jun 2026	Form 4: Gaggar Anuj, Chief Medical Officer Received 14,000 shares as a grant or award
05 Jun 2026	Form 4: White Nicole S, Chief Manufacturing Officer Received 14,000 shares as a grant or award
05 Jun 2026	Form 4: McHutchison John G, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Mahony Susan, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Johnson-Pratt Lisa, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Houghton Michael, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Consylman Gina, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Altig Anthony E, Director Granted 8,000 Stock Option (right to buy)
05 Jun 2026	Form 4: Bjorkquist Jeanette M, PFO and PAO Received 3,500 shares as a grant or award
05 Jun 2026	Form 4: Delaney William E Iv, Chief Scientific Officer Received 14,000 shares as a grant or award
05 Jun 2026	Form 4: Okazaki Jason A, Director Received 50,750 shares as a grant or award
05 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Comments